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Mostafa Ghanei1*, Leila Hoseini Nezhad1, Ali Amini Harandi2, Farshid Alaeddini1, Majid Shohrati1 and Jafar Aslani1Abstract: Background and the purpose of the study
Existing evidence confirms that no pharmacologic agent ameliorates the decline in the lung function or changes
the prognosis of chronic obstructive pulmonary disease (COPD). We tried a critical combination therapy for
management of COPD.
Methods: Current or past smoker (passive or active) COPD patients with moderate to severe COPD who did not
respond to primitive therapy (i.e., oral prednisolone (50 mg in the morning) for 5 days; with Beclomethasone Fort
(3 puff q12h, totally 1500 micrograms/day), Salmeterol (2 puffs q12h, 50 micrograms/puff) and ipratropium bromide
(4 puffs q8h) for two months, enrolled to study. Furthermore they were received N-Acetylcysteine (1200 mg/daily),
Azithromycin (tablet 250 mg/every other day) and Theophylline (100 mg BD).
Results: The study group consisted of 44 men and 4 women, with a mean age and standard deviation of
63.6 ± 12.7 years (range 22–86 years). Thirteen of 48 patients (27.0%) was responder based on 15% increasing in FEV
1 (27.7 ± 7.9) after 6.7 ± 6.1 months (57.9 ± 12.9 year old). There were statistically significant differences in age and
smoking between responders and non-responders (P value was 0.05 and 0.04 respectively). There was no difference
in emphysema and air trapping between two groups (p = 0.13).
Conclusion: Interestingly considerable proportion of patients with COPD can be reversible using combination drug
therapy and patients will greatly benefit from different and synergic action of the drugs. The treatment was more
effective in younger patients who smoke less.
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Worldwide, Chronic obstructive pulmonary disease
(COPD) is the sixth leading cause of death [1] and is the
only condition in the top 10 causes of death with an in-
creasing prevalence and mortality [2]. It has been esti-
mated that COPD will become the third leading cause of
death worldwide by 2020, and its ranking relative for
number of disability-adjusted life-years lost will increase
from 12th to 5th [3]. COPD is characterised by slowly
progressive development of airflow limitation that is
poorly reversible, in sharp contrast to asthma where
there is variable airflow obstruction that is usually re-
versible spontaneously or with treatment. While there
have been major advances in the understanding and
management of asthma, COPD has been relatively* Correspondence: m.ghanei@bmsu.ac.ir
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reproduction in any medium, provided the orneglected and there are no current therapies that reduce
the inevitable progression of this disease.
Currently, oxygen therapy for hypoxemic patients and
cigarette-smoking cessation are the only interventions
known to alter the natural history of COPD and there
are not any drugs to reach this goal till now. Although
existing evidence confirms that no pharmacologic agent
ameliorates the decline in the lung function or changes
the prognosis of COPD, we tried a critical combination
drugs for the management for patients suffering with
COPD. Based on documented medications in patients
with COPD and our recent experience with several
patients have raised the main question in our mind
about whether combination of essential and conven-
tional therapies have sufficient effect to control COPD
and even might reverse underlying pathology in suscep-
tible patients. Furthermore, complementary question
was that which patient with what characters would get
most benefit from this protocol.Ltd This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In a self controlled clinical trial study, we selected current
or past smoker (passive or active) COPD patients who
had compatible symptoms (e.g. dyspnea, cough and
wheezing) and abnormal pulmonary function tests (PFT’s).
Patients were excluded if they had a history of significant
occupational or other environmental exposures, connect-
ive tissue disease, heart failure (evaluated by echocardiog-
raphy) irregular rhythms active pneumonia, tuberculosis
or thrombotic events. In addition, clinical history of any
macrolides in the recent 3 months was considered as ex-
clusion criteria. The protocol of the treatment was
explained for the patients and written informed consent
(approved by the appropriate Institutional Board Review)
was obtained from each patient prior to enrollment. None
of the patients was forced to drop out of the study due to
the type of treatment protocol or side effects. The study
was performed with the approval of the ethics committee
board and in accordance with good clinical practice and
the Declaration of Helsinki.
They had not respond to the following protocol for
two months: oral prednisolone (50 mg in the morning)
for 5 days; with Beclomethasone Fort (3 puff q12h, to-
tally 1500 micrograms/day), Salmeterol (2 puffs q12h, 50
micrograms/puff ) and ipratropium bromide (4 puffs
q8h) for two months, enrolled to study. Furthermore
they were received N-Acetylcysteine (effervescent tablet
1200 mg/daily), Azithromycin (tablet 250 mg/every
other day) and Theophylline (100 mg BD). All patients
were recommended to stop smoking. Undesirable re-
sponse to therapy was considered as remaining of re-
spiratory sign and symptoms and no prominent changes
in PFT. The effectiveness of combination therapy was
measured using PFT and physical examination from
baseline to time that they respond to therapy (i.e., 15%
increasing in FEV1).
In patients with gastroesophageal reflux symptoms
(i.e., heartburn and regurgitation), Omeprazole (20 mg
early in the morning) and Famotidine (40 mg at bed
time) and Metoclopramide HCl (5 mg BD) were added
to their medications.
Chest HRCT technique and interpretation
An axial GE Hi-speed advantage CT scanner (GE med-
ical system, FXI-plus) at 120 kVp and 200–250 mAs
with 1 mm collimation and 10 mm intervals from prox-
imal trachea to the diaphragm was utilized. The scans
were obtained in supine position in deep inspiration and
also in deep expiration. The HRCT films were reviewed
by three expert radiologists using an eFilm workstation
(Merge eFilm).
Air trapping was defined as the presence of a radio-
lucent region of the lungs on expiratory images. The de-
gree of air trapping was assessed by comparing end-inspiratory and expiratory images at similar anatomic
levels and at each of the three levels. Air trapping was
evaluated in three of the four anatomic levels in each
case: upper lung zone, defined as the level of superior
aspect of the aortic arch; middle lung zone, defined as
the level of the carina; and lower lung zone, defined as
the level 5–10 cm below the carina. By using HRCT, em-
physema has been described as presence of low attenu-
ation areas, with ill-defined margins, generally without
visible walls, bullae (pseudocysts that contain air, with
thin well-defined walls), rarefaction of vessels and distor-
tion of the vasculature and complementary signs of
hyperinflation of the lungs [4].
Pulmonary function testing technique and interpretation
Spirometry was performed according to American Thor-
acic Society criteria. The forced vital capacity (FVC) and
FEV1 were measured, under the direction of physicians,
using a standard spirometer (MasterScreen IOS; Jaeger/
Toennies; Hochberg, Germany). Subjects were seated with
a nose clip in place and were asked to perform at least
three forced expiratory maneuvers. Both the patients and
the technician received visual feedback from a monitor
during the test, which was repeated until three technically
satisfactory curves with a reproducible contour were
obtained.
Results
Sixty four participants were included at baseline and 48
patients completed the study. The study group consisted
of 44 men and 4 women, with a mean age and standard
deviation of 63.6 ± 12.7 years (range 22–86 years). Thir-
teen of 48 (27%) patients had improved symptoms
according to PFT’s i.e., 15% increasing in forced expira-
tory volume in 1 second (FEV1) after 6.7 ± 6.1 months.
Characteristics of responder and non responder patients
are shown in detail in Table 1.
Discussion
This study evaluated current approved pharmacotherapy
all together in the treatment of moderate to severe
COPD and provides insight to a guided approach to the
use of different medications in stable COPD. It seems
this combination critically could improve signs and
symptoms and even it could reverse obstruction in con-
siderable proportion of smokers with COPD. In our set-
ting reversibility of 27% of patients is very interesting.
Whereas a new definition of COPD has recently been
adopted by the Global Initiative on Obstructive Lung
Disease (GOLD): "a disease state characterized by airflow
limitation that is not fully reversible [5].
It seems age and smokings are two main factors that
have effect on response of patients to therapy. Specific-
ally younger patients have responded significantly more
Table 1 Characteristics of responder and non responder
patients
Non-responder Responder P value
Number 35 13
Age 65.7 ± 11.9 57.9 ± 12.9 0.054
Sex male 33 11 0.028
female 2 2
Time of follow up 8.8 ± 6.1 6.7 ± 6.1 0.03
FEV1 changes 0.94 ± 9.9 27.7 ± 7.9 0.0001
Smoking Past 21 3 0.044
Current 13 9
Pack per year 44.7 25.4 0.03
HRCT finding Emphysema 12 2 0.13
Air trapping 2 3
Normal 4 0
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ther for longer period or more pack per year had lower
response to therapy. Also it has been shown HRCT find-
ings had no effect on responsiveness.
Because of several pathways of pathogenicity in COPD,
it was supposed that multipurpose therapeutic approach
would be effective by modulating almost all known path-
ways and diminish vicious pathologic circles. However,
this strategy would work properly only in specific setting
and could not be generalized to all patients. Here we
summarized pathogenesis and therapeutic modalities.
Several mechanisms contribute to the pathogenesis of
COPD [6]. First, the inhalation of noxious particles such
as cigarette smoke causes the influx of inflammatory
cells into the airways and lungs, leading to chronic in-
flammation. The airflow limitation is usually progressive
and associated with an abnormal inflammatory response
of the lungs to noxious particles and gases [5]. Over the
past several years, numerous studies have confirmed the
important role of inflammation in the airways and lung
parenchyma of COPD. Many have advocated a central
pathogenic role of this inflammatory response [7-13].
Second, there is a disruption of the balance between
proteolytic and anti-proteolytic molecules in the lungs of
COPD patients, resulting in an increased proteolytic activ-
ity [14]. This causes the destruction of healthy lung paren-
chyma, which leads to the development of emphysema.
This increase in proteolytic activity may be a consequence
of inflammation (release of proteolytic enzymes by inflam-
matory cells such as macrophages and neutrophils) or
may arise from genetic factors (e.g., alpha-1 antitrypsin
deficiency).
A third mechanism involved in the pathogenesis of
COPD is oxidative stress. There is considerable evidence
for increased oxidative stress in COPD [15,16]. It occurs
when reactive oxygen species are produced in excess ofthe antioxidant defense mechanisms [6]. Oxidants are
generated in the airways by cigarette smoking or are
released from inflammatory leukocytes and epithelial
cells. Oxidative stress can lead to four processes (chronic
inflammation, proteinase/anti-proteinase imbalance, oxi-
dative stress and disruption of the balance between
apoptosis and replenishment of structural cells in the
lung might contribute to the destruction of lung tissue
in response to cigarette smoke, leading to emphysema)
involved in the pathogenesis of COPD. These are not in-
dependent mechanisms and several interactions between
these processes occur during the development of the dis-
ease. The oxidative stress can be suppressed by using
anti-oxidant. Whereas epidemiological evidence indi-
cates that reduced dietary intake of antioxidants may be
a determinant of COPD and population surveys have
linked a low dietary intake of the antioxidant ascorbic
acid (vitamin C) with worse lung function [17,18]. Here
we used N-Acetylcysteine as an approved antioxidant.
Treatment by N-Acetylcysteine increased extracellular
total anti-oxidant power and total thiol molecules and
also improved intracellular glutathione and the outcome
of the patients [19]. Also it can reduce viscosity of secre-
tion in the airway of COPD patients.
Corticosteroids and theophylline
In patients with COPD, corticosteroids are ineffective in
suppressing inflammation, including cytokines, chemo-
kines and proteases [20,21]. In vitro the release of IL-8,
TNFa and MMP-9 macrophages from normal subjects
and normal smokers are inhibited by corticosteroids,
whereas corticosteroids are ineffective in macrophages
from patients with COPD [22]. The reasons for resist-
ance to corticosteroids in COPD and to lesser extent
macrophages from smokers may be the marked reduc-
tion in activity of histone deacetylase (HDAC) [22,23],
which is recruited to activated inflammatory genes by
glucocorticoid receptors to switch off inflammatory
genes [24]. The reduction in HDAC activity in macro-
phages is correlated with increased secretion of cyto-
kines like TNFa and IL-8 and reduced response to
corticosteroids. The reduction of HDAC activity on
COPD patients may be mediated through oxidative
stress and peroxynitrite formation. Although corticoster-
oids are not effective in inhibiting the secretion of cyto-
kines and proteases from macrophages, other drugs may
have considerable advantages. Theophylline in low con-
centrations increases HDAC activity in alveolar macro-
phages and in vitro reverses the steroid resistance
induced by oxidative stress [25].
Macrolides
Increasingly, data are becoming available that macrolides
have beneficial effects that are independent of their
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effects may be particularly important in chronic inflam-
matory airway disorders. These latter actions may be of
greatest benefit for selected patients with COPD, a dis-
order characterized by augmented pulmonary inflamma-
tion at baseline, frequent bacterial colonization/infection,
and recurrent exacerbations of disease which further in-
crease lung inflammation. Among their many activities,
macrolides have been shown to exert effects on a wide
range of cells including nasal and bronchial epithelial cells,
alveolar macrophages, monocytes, eosinophils, neutro-
phils and lymphocytes. The effect on signaling pathways
are including NF-κB and AP-1 [26,27].
Neutrophil elastase has subsequently been shown to
have several other actions relevant to its potential role in
COPD. It is a potent mucus secretagogue of submucosal
gland cells and goblet cells [28,29]. The macrolide anti-
biotics erythromycin and flurithromycin have also been
shown to inhibit NE activity [30] and this might account
for their beneficial effect on mucus hypersecretion [31].
Macrolides exert a host of effects that collectively limit
tissue damage by neutrophils. In addition to effects on
chemoattractants, these include inhibiting their oxidant
burst, impairing degranulation, and increasing the rate
of neutrophil apoptosis. There is also evidence that
macrolides decrease mucus viscosity [32]. Importantly,
all these immunomodulatory effects are evident at con-
centrations attainable clinically by low-dose administra-
tion. Hence, macrolides have many properties that could
moderate the neutrophilic inflammation central to air-
way damage, and might also improve aspects of airflow
obstruction.
Macrolides also exert diverse actions that suppress mi-
crobial virulence factors [33-35]. Given these immuno-
modulatory properties and unique effects on bacterial
pathogens macrolide antimicrobial agents have the po-
tential to serve a unique role in the management of
chronic inflammatory lung disorders, including COPD.
H2 receptor antagonist and proton pump inhibitor
In patients with gastroesophageal reflux symptoms the
addition of a bedtime H2 receptor antagonist to proton
pump inhibitor reduces the percentage time of the intra-
gastric pH < 4 and also nocturnal acid breakthrough. H2
receptor antagonist should be considered as adjunct
therapy in whom greater suppression of gastric acid con-
trol is considered desirable [36].
Conclusion
Our study showed 27% of COPD patients have been
improved in FEV1 using combination drug therapy and
patients will greatly benefit from different and synergic
action of the drugs in a 8-month period. It is excellent
advantage in treatment of irreversible disease likeCOPD. The role of chronic combination therapy in these
patients requires additional study to better define a
series of concerns. Any treatment that can lead to re-
versibility of airflow limitation even in small proportion
has a very critical role to improve the disease. Add-
itional, well-designed, placebo-controlled trials are
needed before widespread use of this combination regi-
men for COPD patients.
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